Global drug discovery market worldwide by segment 2016 and 2025

The drug discovery market worldwide is on the rise. By 2025 the market is expected to be valued at 71 billion U.S. dollars. As of 2016, the market was valued at just 35.2 billion U.S. dollars. The largest segment of the drug discovery market has been small molecule drug discovery. By 2025 the small molecule drug discovery market will be valued at some 48 billion U.S. dollars. Top R&D pharmaceutical companies Pharmaceutical research and development (R&D) is an essential part of new drug discovery and manufacturing. The top pharmaceutical companies based on their research and development spending are Roche, Johnson & Johnson and Novartis. It is estimated that by 2024 the top worldwide pharmaceutical companies based on research and development spending will be Johnson & Johnson, Roche and Merck & Co. Research and development trends Research and development in the pharmaceutical industry is an expensive endeavor. Companies are responsible for new drug approvals, clinical trials and are subject to specific rules and regulations. In general, the average cost to develop new drugs has been increasing, despite new technologies. While costs to develop drugs are increasing, returns on investments in research and development are decreasing over time. That is one reason why pharmaceutical companies are increasingly outsourcing R&D to academic or private research contractors.

全球药物发现市场正处于蓬勃发展阶段。预计到2025年，该市场规模将达到710亿美元。截至2016年，市场规模仅为352亿美元。药物发现市场中最大的部分为小分子药物发现。预计到2025年，小分子药物发现市场的规模将达到约480亿美元。在研发投入方面，罗氏、强生和诺华等顶尖制药公司占据领先地位。据估计，到2024年，根据研发投入排名，全球领先的制药公司将是强生、罗氏和默克公司。研发趋势在制药行业中，研发是一项耗资巨大的活动。公司负责新药的审批、临床试验，并受制于特定的规则和法规。总体而言，尽管新技术的发展，开发新药的平均成本一直在上升。然而，随着研发成本的上升，研发投资的回报却在逐渐减少。这正是制药公司越来越多地将研发外包给学术或私人研究承包商的原因之一。